ABSI
Absci Corporation
Price Chart
Latest Quote
$3.02
Current Price| Previous Close | $2.99 |
| Open | $2.93 |
| Day High | $3.09 |
| Day Low | $2.90 |
| Volume | 2,489,947 |
Stock Information
| Shares Outstanding | 150.37M |
| Total Debt | $6.22M |
| Cash Equivalents | $152.48M |
| Revenue | $2.81M |
| Net Income | $-114.60M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $454.12M |
| EPS (TTM) | $-0.91 |
| Exchange | NMS |
📊 Custom Metrics & Score
Score: 14/42| Debt to Equity | 0.06 |
| Debt to Earnings | -0.10 |
| Current Ratio | 4.67 |
| Quick Ratio | 3.92 |
| Avg Revenue Growth | -1.30% |
| Profit Margin | -2274.06% |
| Return on Equity | -57.56% |
| Avg FCF Growth | -6.55% |
| FCF Yield | -16.03% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $3.02 | 2,489,947 |
| 2026-01-30 | $2.99 | 3,264,300 |
| 2026-01-29 | $3.03 | 3,731,800 |
| 2026-01-28 | $2.94 | 2,762,700 |
| 2026-01-27 | $2.98 | 2,216,300 |
| 2026-01-26 | $2.89 | 2,667,700 |
| 2026-01-23 | $2.91 | 3,636,500 |
| 2026-01-22 | $3.16 | 3,066,900 |
| 2026-01-21 | $3.02 | 2,928,100 |
| 2026-01-20 | $2.90 | 4,912,500 |
| 2026-01-16 | $3.02 | 2,729,100 |
| 2026-01-15 | $3.05 | 4,478,100 |
| 2026-01-14 | $3.35 | 2,587,300 |
| 2026-01-13 | $3.31 | 3,212,000 |
| 2026-01-12 | $3.40 | 3,599,600 |
| 2026-01-09 | $3.34 | 7,613,300 |
| 2026-01-08 | $3.44 | 7,408,800 |
| 2026-01-07 | $4.02 | 4,367,900 |
| 2026-01-06 | $3.90 | 2,905,100 |
| 2026-01-05 | $3.74 | 3,538,300 |
About Absci Corporation
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
📰 Latest News
Absci Corporation's (NASDAQ:ABSI) recent 12% pullback adds to one-year year losses, institutional owners may take drastic measures
Simply Wall St. • 2026-01-21T10:51:45Z
Absci Unveils Origin-1 AI Model, Teases 2025 Hair-Loss Data and Q4 Endometriosis Trial Launch
MarketBeat • 2026-01-15T02:07:21Z
Analysts Cut Absci (ABSI) Target, Spotlight New Alopecia Therapy in Early Trials
Insider Monkey • 2026-01-14T19:13:49Z
Absci Unveils Preclinical Data for AI-Designed ABS-201, Targeting a Novel Hormonal Pathway for Hair Loss Treatment
Insider Monkey • 2025-12-31T16:13:00Z
Absci Corporation (ABSI) Announces First Participants Dosed In Phase 1/2a HEADLINE Trial
Insider Monkey • 2025-12-30T17:18:37Z
Absci Corporation (ABSI) Draws Full Buy Consensus With 150% Upside Potential
Insider Monkey • 2025-12-27T12:43:11Z
Absci Corporation (NASDAQ:ABSI)’s ABS‑201 Shows Promise in Hair Loss Treatment, Analysts See Upside
Insider Monkey • 2025-12-18T06:14:49Z
Independent Director of Absci Picks Up 454% More Stock
Simply Wall St. • 2025-12-11T18:47:00Z
Absci (ABSI) Is Up 12.9% After Starting Phase 1/2a Trials For AI-Designed ABS-201
Simply Wall St. • 2025-12-06T02:07:47Z
ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study
Zacks • 2025-12-05T15:37:00Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $4,534,000 | $5,718,000 | $5,747,000 | $4,782,000 |
| Operating Revenue | $4,534,000 | $5,718,000 | $5,747,000 | $4,782,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $565,000 | $1,010,000 | $972,000 | $3,432,000 |
| Total Expenses | $113,422,000 | $99,898,000 | $112,497,000 | $80,020,000 |
| Other Income Expense | $6,417,000 | $-15,276,000 | $2,357,000 | $-31,189,000 |
| Other Non Operating Income Expenses | $6,417,000 | $6,059,000 | $2,357,000 | $-31,189,000 |
| Net Non Operating Interest Income Expense | $-565,000 | $-1,010,000 | $-972,000 | $-3,432,000 |
| Interest Expense Non Operating | $565,000 | $1,010,000 | $972,000 | $3,432,000 |
| Operating Expense | $113,422,000 | $99,898,000 | $112,497,000 | $80,020,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-103,106,000 | $-110,566,000 | $-104,904,000 | $-100,960,000 |
| Net Interest Income | $-565,000 | $-1,010,000 | $-972,000 | $-3,432,000 |
| Normalized Income | $-103,106,000 | $-93,711,350 | $-104,904,000 | $-100,960,000 |
| Net Income From Continuing And Discontinued Operation | $-103,106,000 | $-110,566,000 | $-104,904,000 | $-100,960,000 |
| Total Operating Income As Reported | $-108,888,000 | $-115,515,000 | $-106,750,000 | $-75,238,000 |
| Net Income Common Stockholders | $-103,106,000 | $-110,566,000 | $-104,904,000 | $-103,244,000 |
| Net Income | $-103,106,000 | $-110,566,000 | $-104,904,000 | $-100,960,000 |
| Net Income Including Noncontrolling Interests | $-103,106,000 | $-110,566,000 | $-104,904,000 | $-100,960,000 |
| Net Income Continuous Operations | $-103,106,000 | $-110,566,000 | $-104,904,000 | $-100,960,000 |
| Pretax Income | $-103,036,000 | $-110,466,000 | $-105,365,000 | $-109,859,000 |
| Special Income Charges | $0 | $-21,335,000 | $0 | - |
| Operating Income | $-108,888,000 | $-94,180,000 | $-106,750,000 | $-75,238,000 |
| Depreciation Amortization Depletion Income Statement | $13,389,000 | $13,999,000 | $13,037,000 | $6,654,000 |
| Depreciation And Amortization In Income Statement | $13,389,000 | $13,999,000 | $13,037,000 | $6,654,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-0.94 | $-1.20 | $-1.15 | $-2.08 |
| Basic EPS | $-0.94 | $-1.20 | $-1.15 | $-2.08 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $-4,480,350 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-89,082,000 | $-74,122,000 | $-91,293,000 | $-99,773,000 |
| Total Unusual Items | $0 | $-21,335,000 | $0 | - |
| Total Unusual Items Excluding Goodwill | $0 | $-21,335,000 | $0 | - |
| Reconciled Depreciation | $13,389,000 | $13,999,000 | $13,100,000 | $6,654,000 |
| EBITDA (Bullshit earnings) | $-89,082,000 | $-95,457,000 | $-91,293,000 | $-99,773,000 |
| EBIT | $-102,471,000 | $-109,456,000 | $-104,393,000 | $-106,427,000 |
| Diluted Average Shares | $110,239,870 | $92,028,016 | $90,845,629 | $49,685,194 |
| Basic Average Shares | $110,239,870 | $92,028,016 | $90,845,629 | $49,685,194 |
| Diluted NI Availto Com Stockholders | $-103,106,000 | $-110,566,000 | $-104,904,000 | $-103,244,000 |
| Tax Provision | $70,000 | $100,000 | $-461,000 | $-8,899,000 |
| Impairment Of Capital Assets | $0 | $21,335,000 | $0 | - |
| Research And Development | $63,859,000 | $48,067,000 | $58,908,000 | $44,586,000 |
| Selling General And Administration | $36,174,000 | $37,832,000 | $40,552,000 | $28,780,000 |
| Otherunder Preferred Stock Dividend | - | - | - | $0 |
| Preferred Stock Dividends | - | - | - | $2,284,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $134,250,000 | $127,923,000 | $201,457,000 | $289,780,000 |
| Total Assets | $213,608,000 | $217,298,000 | $321,008,000 | $426,195,000 |
| Total Non Current Assets | $79,777,000 | $96,720,000 | $134,145,000 | $153,116,000 |
| Other Non Current Assets | $1,759,000 | $2,649,000 | $3,146,000 | $18,137,000 |
| Goodwill And Other Intangible Assets | $44,883,000 | $48,253,000 | $72,957,000 | $76,327,000 |
| Other Intangible Assets | $44,883,000 | $48,253,000 | $51,622,000 | $54,992,000 |
| Current Assets | $133,831,000 | $120,578,000 | $186,863,000 | $273,079,000 |
| Other Current Assets | $5,459,000 | $4,537,000 | $5,859,000 | $8,572,000 |
| Restricted Cash | $15,947,000 | $16,193,000 | $15,023,000 | $10,513,000 |
| Receivables | $0 | $2,189,000 | $1,550,000 | $1,425,000 |
| Accounts Receivable | $0 | $2,189,000 | - | - |
| Cash Cash Equivalents And Short Term Investments | $112,425,000 | $97,659,000 | $164,431,000 | $252,569,000 |
| Cash And Cash Equivalents | $41,213,000 | $72,362,000 | $59,955,000 | $252,569,000 |
| Other Receivables | - | $2,189,000 | $1,550,000 | $1,425,000 |
| Prepaid Assets | - | - | - | $8,572,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $10,105,000 | $15,881,000 | $22,983,000 | $20,011,000 |
| Long Term Debt And Capital Lease Obligation | $5,686,000 | $10,303,000 | $16,051,000 | $13,324,000 |
| Long Term Debt | $1,257,000 | $4,660,000 | $7,984,000 | $1,124,000 |
| Current Debt And Capital Lease Obligation | $4,419,000 | $5,578,000 | $6,932,000 | $6,687,000 |
| Current Debt | $2,733,000 | $3,258,000 | $2,946,000 | $2,400,000 |
| Other Current Borrowings | $2,733,000 | $3,258,000 | $2,946,000 | $2,400,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $34,475,000 | $41,122,000 | $46,594,000 | $60,088,000 |
| Total Non Current Liabilities Net Minority Interest | $5,819,000 | $11,564,000 | $16,324,000 | $26,229,000 |
| Other Non Current Liabilities | $133,000 | $295,000 | $35,000 | $12,162,000 |
| Non Current Deferred Liabilities | $0 | $966,000 | $238,000 | $743,000 |
| Current Liabilities | $28,656,000 | $29,558,000 | $30,270,000 | $33,859,000 |
| Other Current Liabilities | $12,750,000 | $12,750,000 | - | - |
| Current Deferred Liabilities | $1,116,000 | $3,174,000 | $445,000 | $1,353,000 |
| Payables And Accrued Expenses | $10,371,000 | $8,056,000 | $22,893,000 | $25,819,000 |
| Payables | $3,529,000 | $1,503,000 | $2,412,000 | $8,385,000 |
| Accounts Payable | $3,529,000 | $1,503,000 | $2,412,000 | $8,385,000 |
| Non Current Deferred Taxes Liabilities | - | $186,000 | $238,000 | $743,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $179,133,000 | $176,176,000 | $274,414,000 | $366,107,000 |
| Total Equity Gross Minority Interest | $179,133,000 | $176,176,000 | $274,414,000 | $366,107,000 |
| Stockholders Equity | $179,133,000 | $176,176,000 | $274,414,000 | $366,107,000 |
| Gains Losses Not Affecting Retained Earnings | $-4,000 | $-37,000 | $-120,000 | $-13,000 |
| Other Equity Adjustments | $-4,000 | $-37,000 | $-120,000 | $-13,000 |
| Retained Earnings | $-509,601,000 | $-406,495,000 | $-295,929,000 | $-191,025,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $115,362,265 | $93,087,675 | $92,411,103 | $92,648,036 |
| Share Issued | $115,362,265 | $93,087,675 | $92,411,103 | $92,648,036 |
| Tangible Book Value | $134,250,000 | $127,923,000 | $201,457,000 | $289,780,000 |
| Invested Capital | $183,123,000 | $184,094,000 | $285,344,000 | $369,631,000 |
| Working Capital | $105,175,000 | $91,020,000 | $156,593,000 | $239,220,000 |
| Capital Lease Obligations | $6,115,000 | $7,963,000 | $12,053,000 | $16,487,000 |
| Total Capitalization | $180,390,000 | $180,836,000 | $282,398,000 | $367,231,000 |
| Additional Paid In Capital | $688,726,000 | $582,699,000 | $570,454,000 | $557,136,000 |
| Capital Stock | $12,000 | $9,000 | $9,000 | $9,000 |
| Common Stock | $12,000 | $9,000 | $9,000 | $9,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $0 | $966,000 | $0 | - |
| Long Term Capital Lease Obligation | $4,429,000 | $5,643,000 | $8,067,000 | $12,200,000 |
| Current Deferred Revenue | $1,116,000 | $3,174,000 | $445,000 | $1,353,000 |
| Current Capital Lease Obligation | $1,686,000 | $2,320,000 | $3,986,000 | $4,287,000 |
| Current Accrued Expenses | $6,842,000 | $6,553,000 | $20,481,000 | $17,434,000 |
| Net PPE | $33,135,000 | $45,818,000 | $58,042,000 | $58,652,000 |
| Accumulated Depreciation | $-31,569,000 | $-23,991,000 | $-15,203,000 | $-6,381,000 |
| Gross PPE | $64,704,000 | $69,809,000 | $73,245,000 | $65,033,000 |
| Leases | $27,057,000 | $27,049,000 | $26,860,000 | $24,671,000 |
| Other Properties | $31,262,000 | $36,588,000 | $39,487,000 | $34,314,000 |
| Machinery Furniture Equipment | $6,385,000 | $6,172,000 | $6,605,000 | $5,115,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $71,212,000 | $25,297,000 | $104,476,000 | $0 |
| Goodwill | - | $0 | $21,335,000 | $21,335,000 |
| Construction In Progress | - | $0 | $293,000 | $933,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-72,806,000 | $-65,496,000 | $-97,514,000 | $-98,645,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-72,402,000 | $-64,636,000 | $-81,339,000 | $-60,598,000 |
| Cash Flow From Continuing Operating Activities | $-72,402,000 | $-64,636,000 | $-81,276,000 | $-60,598,000 |
| Operating Gains Losses | - | - | - | $4,124,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-404,000 | $-860,000 | $-16,175,000 | $-38,047,000 |
| Investing Cash Flow | $-41,577,000 | $81,944,000 | $-126,982,000 | $-67,377,000 |
| Cash Flow From Continuing Investing Activities | $-41,577,000 | $81,944,000 | $-126,982,000 | $-67,377,000 |
| Net Other Investing Changes | - | - | $650,000 | - |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $86,557,000 | $862,000 | $656,000 | $215,340,000 |
| Financing Cash Flow | $82,526,000 | $-4,483,000 | $5,237,000 | $336,193,000 |
| Cash Flow From Continuing Financing Activities | $82,526,000 | $-4,483,000 | $5,237,000 | $336,193,000 |
| Net Common Stock Issuance | $86,557,000 | $862,000 | $656,000 | $210,396,000 |
| Common Stock Issuance | $86,557,000 | $862,000 | $656,000 | $210,396,000 |
| Net Preferred Stock Issuance | - | - | $0 | $4,944,000 |
| Preferred Stock Issuance | - | - | $0 | $4,944,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-4,031,000 | $-5,345,000 | $-7,450,000 | $-4,147,000 |
| Interest Paid Supplemental Data | $561,000 | $970,000 | $895,000 | $652,000 |
| End Cash Position | $58,214,000 | $89,667,000 | $76,842,000 | $279,926,000 |
| Beginning Cash Position | $89,667,000 | $76,842,000 | $279,926,000 | $71,708,000 |
| Changes In Cash | $-31,453,000 | $12,825,000 | $-203,084,000 | $208,218,000 |
| Net Issuance Payments Of Debt | $-4,031,000 | $-5,345,000 | $4,581,000 | $120,853,000 |
| Net Long Term Debt Issuance | $-4,031,000 | $-5,345,000 | $4,581,000 | $120,853,000 |
| Long Term Debt Payments | $-4,031,000 | $-5,345,000 | $-7,450,000 | $-4,147,000 |
| Net Investment Purchase And Sale | $-42,112,000 | $82,550,000 | $-103,590,000 | $-1,200,000 |
| Sale Of Investment | $144,000,000 | $229,897,000 | $5,000,000 | $0 |
| Purchase Of Investment | $-186,112,000 | $-147,347,000 | $-108,590,000 | $-1,200,000 |
| Net PPE Purchase And Sale | $535,000 | $-606,000 | $-16,042,000 | $-38,047,000 |
| Sale Of PPE | $939,000 | $254,000 | $133,000 | $0 |
| Purchase Of PPE | $-404,000 | $-860,000 | $-16,175,000 | $-38,047,000 |
| Change In Working Capital | $-368,000 | $1,517,000 | $-1,540,000 | $-3,146,000 |
| Change In Other Working Capital | $-3,786,000 | $2,839,000 | $-1,547,000 | $1,979,000 |
| Change In Other Current Assets | $-68,000 | $-255,000 | $13,000 | $126,000 |
| Change In Payables And Accrued Expense | $1,731,000 | $-1,999,000 | $-2,240,000 | $2,155,000 |
| Change In Accrued Expense | $-295,000 | $-1,213,000 | $-1,707,000 | $581,000 |
| Change In Payable | $2,026,000 | $-786,000 | $-533,000 | $1,574,000 |
| Change In Account Payable | $2,026,000 | $-786,000 | $-533,000 | $1,574,000 |
| Change In Prepaid Assets | $-484,000 | $1,598,000 | $2,382,000 | $-7,636,000 |
| Change In Receivables | $2,239,000 | $-666,000 | $-148,000 | $230,000 |
| Changes In Account Receivables | $2,239,000 | $-666,000 | - | - |
| Other Non Cash Items | $1,974,000 | $334,000 | $658,000 | $31,023,000 |
| Stock Based Compensation | $19,452,000 | $11,416,000 | $12,540,000 | $10,608,000 |
| Asset Impairment Charge | $0 | $21,335,000 | $0 | - |
| Amortization Of Securities | $-3,743,000 | $-2,671,000 | $-688,000 | $0 |
| Depreciation Amortization Depletion | $13,389,000 | $13,999,000 | $13,100,000 | $6,654,000 |
| Depreciation And Amortization | $13,389,000 | $13,999,000 | $13,100,000 | $6,654,000 |
| Net Income From Continuing Operations | $-103,106,000 | $-110,566,000 | $-104,904,000 | $-100,960,000 |
| Issuance Of Debt | - | $0 | $12,031,000 | $125,000,000 |
| Long Term Debt Issuance | - | $0 | $12,031,000 | $125,000,000 |
| Net Business Purchase And Sale | - | $0 | $-8,000,000 | $-28,130,000 |
| Purchase Of Business | - | $0 | $-8,000,000 | $-28,130,000 |
| Deferred Tax | - | $-52,000 | $-505,000 | $-8,901,000 |
| Deferred Income Tax | - | $-52,000 | $-505,000 | $-8,901,000 |
| Amortization Cash Flow | - | $3,400,000 | $3,400,000 | - |
| Amortization Of Intangibles | - | $3,400,000 | $3,400,000 | - |
| Depreciation | - | $10,600,000 | $9,700,000 | - |
| Gain Loss On Investment Securities | - | - | - | $4,124,000 |
| Net Foreign Currency Exchange Gain Loss | - | - | - | $-11,000 |